Insmed is trading $135.59 (+9.44%) after Japan approved Brinsupri for non-cystic fibrosis bronchiectasis in adults and eligible children on August 24, 2026; this company-specific catalyst best explains the pre-market strength.
- Japan’s MHLW approval completes Brinsupri’s U.S., European, and Japanese regulatory expansion and expands its commercial opportunity.
- Mizuho subsequently raised its price target to $195 from $192 while maintaining an Outperform rating.
- Broader markets were largely mixed, limiting macro explanation.